Stockwinners Market Radar for September 25, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment bought 207.6K shares of Markforged today

18:02 EDT Fat Brands acquires Smokey Bones barbecue chain from Sun Capital affiliate - FAT Brands announces it has acquired the Smokey Bones Bar & Fire Grill restaurant chain from an affiliate of Sun Capital Partners. The acquisition marks the company's first foray into barbecue and expands FAT Brands' portfolio of polished dining chains, which currently includes Twin Peaks. The purchase is expected to increase annual adjusted EBITDA by approximately $10M, and bring 61 new corporate locations under FAT Brands' umbrella. The $30M transaction was funded from the company's existing securitization facilities.

17:40 EDT Digital Media Solutions to be delisted from NYSE - Digital Media Solutions announced that it will be delisted from the New York Stock Exchange. The company's delisting follows the NYSE's determination under Rule 802.01B of the NYSE Listed Company Manual that the company did not meet the NYSE's continued listing standard that requires listed companies to maintain an average global market capitalization of at least $15 million over a period of 30 consecutive trading days. The company's delisting does not affect the company's business operations and DMS continues to be focused on its core solutions in service of its advertising clients. In addition, the delisting does not cause an event of default under the senior secured credit facility to which its subsidiaries are a party, and DMS continues to be supported by its lenders as evidenced by the recent amendment to its credit facility, which has provided the company and management with the flexibility needed to manage through the current environment. The company will continue to be a SEC reporting company and anticipates that its Class A common stock will begin trading on the over-the-counter markets on September 26, 2023. The company will consider relisting its Class A common stock on a national securities exchange in the future if the Board of Directors determines that doing so is in the best interest of the company and its stakeholders.

17:26 EDT Femasys gets FDA clearance to market FemaSeed - Femasys "announced it has received 510(k) Clearance from the United States Food and Drug Administration for FemaSeed(R), an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube. In recent decades, infertility has affected an increasing number of women - estimated at 10 million in the United States according to the Center for Disease Control. Despite incremental advancements, there have been no recent meaningful affordable options. FemaSeed Intratubal Insemination is a type of an intrauterine insemination procedure that is less invasive than in vitro fertilization or intracytoplasmic sperm injection, which we expect would reduce the chances of procedural complications."

17:16 EDT RTX awarded $163.3M U.S. Navy contract - Raytheon Technologies is awarded a $163,260,473 cost-plus-incentive-fee, fixed-price incentive modification to a previously awarded contract. This modification exercises options to procure spare engines, power modules, special test equipment, and special tooling in support of Lot 17 F135 propulsion systems for the F-35 Lighting II Joint Strike Fighter aircraft for the Air Force, Marine Corps, Navy, non-U.S. Department of Defense participants, cooperative program partners, and Foreign Military Sales customers.

17:15 EDT Ultragenyx launches Evkeeza in Canada for treatment of HoFH - Ultragenyx Pharmaceutical announced the approval of Evkeeza in Canada. Evkeeza was approved by Health Canada as an adjunct to diet and other low-density lipoprotein cholesterol lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia and will be commercially available in Canada effective 25-November-2023. Evkeeza is a first-of-its-kind treatment for HoFH and is the first monoclonal antibody inhibiting the angiopoietin-like 3 protein. Evkeeza is delivered via 60-minute intravenous infusion every 4 weeks. The treatment is now available to prescribe for patients with HoFH in Canada.

17:00 EDT Thor falls after quarterly results and guidance amid mixed economic enviroment - Shares of recreational vehicles maker Thor Industries (THO) are down $1.67 in after-market trading on Monday after the company forecasted FY24 EPS of $6.25 to $7.25 on revenue of $10.5B to $11B. Analysts were modeling EPS of $7.12 on revenue of $10.81B. A company officer noted in the release that, "Despite mixed economic data and consumer trends that are expected to continue into fiscal 2024, our experienced operating management teams and proven business model continue to give us an advantage in navigating uncertainty." ..."We continue to invest in automation projects that enhance product quality and drive labor efficiencies without sacrificing our variable cost model. Additionally, we continue to pursue and build out supply and aftermarket strategies aimed at improving the experience for the end consumer. Lastly, through strong strategic partnerships and organic R&D, we continue to take a thoughtful approach to investing in innovation to ensure we stay ahead of the industry and consumer demand. Overall, we are focused on leveraging our global scale as the worldwide RV market leader to support our long-term growth strategies, and we remain committed to achieving our fiscal 2027 financial targets," concluded Todd Woelfer, Senior Vice President and Chief Operating Officer. Other companies in the Consumer Cyclical space include: Winnebago (WGO), LCI Industries (LCII), Polaris (PII)Malibu Boats (MBUU) and Camping World (CWH).

16:49 EDT Ra Capital discloses $8.2M purchase of ARS Pharmaceuticals - RA Capital increases its stake in ARS Pharmaceuticals by 2.7M shares to 9.5M shares with a stock purchase of $8.2M. Shares of ARS Pharmaceuticals are up 5.8% afterhours at $3.81.

16:36 EDT Inspirato appoints Eric Grosse CEO - Inspirato announced that co-founder and CEO Brent Handler has stepped down while remaining a member of the board. Inspirato's board has appointed Eric Grosse to serve as CEO effective September 25. Grosse brings more than 20 years of experience as a leader in the online travel industry, including as co-founder and president of Hotwire and president of Expedia Worldwide, a subsidiary of Expedia Group (EXPE). Grosse has served on the company's board or two years.

16:30 EDT a.k.a. Brands board approves reverse stock split ratio - a.k.a. Brands announced that it will effect a one-for-12 reverse stock split of its common stock, par value $0.001 per share, that will become effective on September 29, 2023 at 5:01 PM Eastern Time, after the close of trading on the New York Stock Exchange. On October 2, 2023, the Company's common stock will begin trading on a post-reverse split basis on the NYSE under the existing symbol "AKA." The reverse split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the NYSE.

16:18 EDT Gray Television announces launch of Peachtree Sports Network - Peachtree Sports Network, Gray Television's newest sports broadcast channel, will launch Sunday, October 1 on WPCH 17.2. The channel will focus on live, local sports programming all year long and will feature teams from multiple sports across the state. The broadcast network will launch in Atlanta but will soon air on Gray-owned over-the-air channels in Albany, Augusta, Columbus, Macon, and Savannah in the coming months. Peachtree Sports Network will broadcast live games from the College Park Skyhawks of the NBA G-League, high school football through Score Atlanta, hockey from the Atlanta Gladiators and the Savannah Ghost Pirates of the ECHL, the Georgia Swarm of the National Lacrosse League, and ultimate disc from the Atlanta Hustle of the American Ultimate Disc League.

16:13 EDT FDA accepts NDA submission to add to Liquidia's Yutrepia label - Liquidia Corporation announced that the FDA accepted for review the company's amendment to the tentatively approved new drug application, NDA, for Yutrepia inhalation powder in which the company is seeking to add the treatment of pulmonary hypertension associated with interstitial lung disease, PH-ILD, to the label. The FDA confirmed the type of resubmission as Class II and has set a Prescription Drug User Fee Act, PDUFA, goal date of January 24, 2024. The FDA tentatively approved Yutrepia to treat PAH in November 2021 and confirmed that the addition of the PH-ILD indication will not require any new clinical studies. The launch of Yutrepia in both indications remains subject to the successful resolution of the ongoing litigation with United Therapeutics and final FDA approval. Additionally, the FDA may not grant final approval of the PH-ILD indication until after the new clinical investigation exclusivity granted to Tyvaso expires on March 31, 2024.

16:11 EDT Voxeljet jumps 31% to $1.44 after announcing strategic alternative review

16:09 EDT Profound Medical receives 510k clearance from FDA for TULSA-PRO Thermal Boost - Profound Medical announced that it has received 510k clearance from the U.S. Food and Drug Administration for the Company's Thermal Boost module for use in conjunction with TULSA-PRO. TULSA-PRO enables surgeons to ablate whole- or partial-gland prostate tissue in patients with low-, intermediate-, or high-risk prostate cancer; with benign prostatic hyperplasia BPH ; as well as those prostate cancer patients on active surveillance seeking treatment of their cancer and relief from their symptoms of BPH. Profound's data indicates that, in a commercial setting, approximately 60% of the patients being treated with TULSA require whole gland ablation, whereas the remaining 40% receive partial gland ablation. In addition, TULSA surgeons are treating prostates of various shapes and sizes, ranging from prostate volumes of less than 20cc to greater than 250cc, confirming TULSA-PRO as one of the most versatile technologies currently available for the treatment of prostate disease...Profound is continuing to develop additional TULSA AI modules, including one that will enable the creation of an AI-driven automated treatment plan, which will be based on a database of successful physician-created treatment designs. The Company is working with the FDA on a pathway to achieve the Agency's clearance for this module.

16:07 EDT Digital Media Solutions Inc trading halted, news pending

16:07 EDT Envestnet names Joshua Warren as CFO, succeeding Pete D'Arrigo - Envestnet announced that Joshua Warren is joining the company as CFO. Warren is an accomplished financial executive who served most recently as Managing Director and Global Head of Business Strategy for iShares and Index Investments for BlackRock. Warren will succeed Peter D'Arrigo who served as CFO since 2008. Warren will initially serve as a senior advisor to the company's CEO and will transition to become the company's CFO effective November 15, 2023. After the transition of CFO responsibilities, D'Arrigo will serve as a senior advisor to the company's CEO through March 31, 2024. Warren will work with D'Arrigo, in the interim, to assure a smooth transition.

16:02 EDT B. Riley Financial increases investment in bebe stores - B. Riley Financial (RILY) announced it has signed an agreement to purchase 3.7M shares of common stock of bebe stores (BEBE) from trusts formed by bebe founder, Manny Mashouf, at $5.00 per share for a total purchase price of $18.5M. The closing date of the transaction is expected to occur on September 30, subject to the satisfaction of certain closing conditions. Upon the closing of the transaction, B. Riley's total ownership of bebe will be approximately 76% of the shares of common stock outstanding. Mashouf, who plans to step down from his roles at bebe in the near future, will continue to own approximately 4% of bebe's outstanding shares of common stock.

14:17 EDT American Software adopts 10b5-1 trading plan for share repurchase program - American Software announced that it has entered into a Rule 10b5-1 trading plan to facilitate stock buybacks under an existing share repurchase program previously approved by the board of directors. There are 946,321 shares available for repurchase under the existing authorization. "We remain committed to strategically deploying capital to create long-term shareholder value. Our robust balance sheet and consistent cash flow generation provide us with ample capacity to execute our M&A strategy, as evidenced by our recent acquisition of AI forecasting pioneer Garvis, while returning capital to our stockholders through our quarterly dividend and share repurchases," said Allan Dow, CEO of American Software.

13:20 EDT Air France-KLM to place order for 50 Airbus A350 family aircraft - The Air France-KLM Group (AFLYY) plans to place a landmark aircraft order to pursue the renewal and rationalization of its long-haul fleet, to the benefit of the Group's environmental and economic performance. This Group order will cover 50 Airbus (EADSY) A350-900 and A350-1000 aircraft - with purchase rights for 40 additional aircraft - with first deliveries expected in 2026 through to 2030. These aircraft will replace previous-generation aircraft, namely Airbus A330 and older Boeing (BA) 777 aircraft. This new order will come in addition to an existing Air France-KLM order for 41 Airbus A350-900s for Air France, of which 22 have been delivered to date. Air France-KLM will also be among the launch customers of the Airbus A350 Full Freighter version of the aircraft, having ordered 8 aircraft to renew and expand its cargo fleet. As of September 25, 2023, Air France-KLM operated a fleet of 533 aircraft to over 300 destinations worldwide. Once this order is placed, the Group will have over 220 aircraft on order, including 100 Airbus A320neo family aircraft, with first deliveries expected by the end of 2023. This order remains subject to standard company approvals. Reference Link

12:00 EDT Alcoa falls -4.9% - Alcoa is down -4.9%, or -$1.40 to $26.95.

12:00 EDT Williams-Sonoma rises 9.4% - Williams-Sonoma is up 9.4%, or $13.21 to $153.22.

12:00 EDT Sea Limited rises 11.0% - Sea Limited is up 11.0%, or $3.96 to $39.92.

11:21 EDT WSFS names Beasley Bradley chief auditor, Goodman general counsel - WSFS Bank announced the hires of Alyson Beasley Bradley as Senior Vice President, Chief Auditor; Jeffrey Goodman as Senior Vice President, General Counsel; and Frank McGrane as Senior Vice President, Deputy Chief Credit Officer. In her new role, Beasley Bradley will report to Christine Davis, Executive Vice President, Chief Risk Officer. She will lead the Internal Audit Department and will oversee the continuous development and implementation of a comprehensive and effective internal audit program throughout the Company, including its subsidiary companies. In addition, she will work in partnership with WSFS' Independent Public Accounting firm and assume a lead management role for the Audit Committee of the Board of Directors. In his new role, Goodman will report to Lisa Washington, Senior Vice President, Chief Legal Officer, and will serve as the primary support and advisor to the Commercial division. In his new role, McGrane will report to Liam Brickley, Senior Vice President, Chief Credit Officer, and will have a senior leadership role in Commercial and Consumer credit administration, approval and policy matters. Prior to joining WSFS, Beasley Bradley served as Chief Audit Executive at Freedom Mortgage Corporation. Goodman served as Contract Counsel at Wells Fargo. McGrane served as Executive Vice President and Senior Credit Officer for Citizens Bank.

10:05 EDT GE Vernova signs MoC with Ukrhydroenergo - GE Vernova announced the signing of a Memorandum of Collaboration between its Hydro Power business and Ukrhydroenergo, Ukraine's largest operator of hydropower plants. As part of the two-year agreement, both companies will seek to identify opportunities to build and restore Ukraine's hydropower facilities. In particular, the MoC identifies a new pumped storage plant of Kaniv, the supply of 3 units of 324MW for the Dniester power plant, and the reconstruction of Kakhovka power plant, which was damaged during the war. This MoC provides a framework for potential contractual agreements in the future. "We are proud of this collaboration we are initiating with Ukrhydroenergo. These facilities are critical to powering Ukrainian houses, schools, hospitals and businesses with clean and reliable electricity," explained Frederic Ribieras, CEO of GE Vernova's Hydro Power business.

10:00 EDT GlobalFoundries applies for U.S. CHIPS and Science Act Funding - GlobalFoundries announced it has applied for U.S. CHIPS and Science Act Funding, with two full applications submitted to the CHIPS Program Office of the U.S. Department of Commerce. The submitted applications are for capacity expansion and modernization of GF's U.S. manufacturing facilities.

10:00 EDT Alcoa falls -5.3% - Alcoa is down -5.3%, or -$1.49 to $26.86.

10:00 EDT Joby Aviation rises 7.8% - Joby Aviation is up 7.8%, or 48c to $6.70.

10:00 EDT Solo Brands rises 8.2% - Solo Brands is up 8.2%, or 37c to $4.88.

09:47 EDT Nio falls -6.7% - Nio is down -6.7%, or -57c to $7.96.

09:47 EDT Super Group falls -7.4% - Super Group is down -7.4%, or -26c to $3.24.

09:47 EDT Williams-Sonoma rises 5.2% - Williams-Sonoma is up 5.2%, or $7.34 to $147.35.

09:45 EDT Nymox announces submission of MAA for Nymozarfex for BPH - Nymox Pharmaceutical announced that a new formal submission has been made by the company in the U.K. for Nymozarfex for the treatment of benign prostatic hyperplasia. The Marketing Authorization Application was submitted to the U.K. Medicines & Healthcare products Regulatory Agency. The new submission includes England, Wales, Scotland and Northern Ireland. The company will provide further information, including with respect to other submissions for Nymozarfex, when the information becomes available. Paul Averback MD, CEO of Nymox said, "We thank our team members and many very important expert collaborators for their efforts and perseverance involved in the ongoing process. This product is a major innovation and there is a great need for men throughout the world to have access to this technology, which is unique. We will continue to provide updates and all relevant communications whenever appropriate. The Company is very grateful for the solid support of our valued stakeholders."

09:42 EDT Golden Heaven Group Holdings Ltd trading resumes

09:37 EDT Knightscope to provide Penn Entertainment with technology services - Knightscope (KSCP) announced that it has signed an agreement with PENN Entertainment (PENN) to offer Knightscope technologies to its 43 gaming and racing properties nationwide. Knightscope recently deployed its first K5 Autonomous Security Robot at Penn Entertainment's M Resort Spa Casino in Nevada, followed by subsequent deployments at Ameristar Casino Hotel Council Bluffs in Iowa and Hollywood Casino Aurora in Illinois. "PENN Entertainment's commitment to safety and the guest experience is extraordinary," said William Santana Li, chairman and CEO at Knightscope. "We are overjoyed that we will be providing Knightscope technologies across its portfolio to protect the surge of guests arriving and departing from all of its properties daily."

09:32 EDT Golden Heaven Group Holdings Ltd trading halted, volatility trading pause

09:28 EDT Iconic Sports Acquisition Corp trading halted, news pending

09:24 EDT Synopsys, TSMC collaborate to accelerate 2nm innovation - Synopsys (SNPS) announced that its digital and custom/analog design flows are certified for TSMC's (TSM) N2 process technology, enabling faster delivery of advanced-node SoCs with higher quality. Both flows are seeing strong momentum, with the digital design flow achieving multiple tape-outs and the analog design flow adopted for several design starts. The design flows, powered by the Synopsys.ai full-stack AI-driven EDA suite, deliver a significant lift in productivity. Synopsys Foundation and Interface IP in development for the TSMC N2 process will help reduce integration risk and speed time to market for advanced HPC, AI, and mobile SoCs. Additionally, Synopsys AI-driven design technologies, including Synopsys DSO.ai, are enabled to fast-path the optimization of N2 design to improve the power, performance, and area.

09:19 EDT Diana Shipping announces time charter contracts for m/v DSI Pyxis, m/v Maia - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with ASL Bulk Marine Limited for one of its Ultramax dry bulk vessels, the m/v DSI Pyxis. The gross charter rate is $14,250 per day, minus a 5% commission paid to third parties, for a period until minimum October 10, 2024 up to maximum December 10, 2024. The charter commenced on September 24, 2023. The "DSI Pyxis" is a 60,362 dwt Ultramax dry bulk vessel built in 2018. The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with ST Shipping and Transport Pte. Ltd., for one of its Kamsarmax dry bulk vessels, the m/v Maia. The gross charter rate is $13,500 per day, minus a 5% commission paid to third parties, for a period until minimum June 15, 2024 up to maximum August 20, 2024. The charter commenced on September 23, 2023. The "Maia" is a 82,193 dwt Kamsarmax dry bulk vessel built in 2009. The employments of "DSI Pyxis" and "Maia" are anticipated to generate approximately $8.91 million of gross revenue for the minimum scheduled periods of the time charters.

09:14 EDT Hanryu Holdings collaborates with NON Corp. to sell Dr. Clo products - Hanryu Holdings announced collaborating with NON Corp. to sell its leading Dr. Clo branded products on the FANTOO application with the marketing assistance of its flagship digital character, DeokGom. Established in 2016, NON owns an intellectual property portfolio for organic disinfectants, deodorants, and infection prevention products. As of 2021, NON's flagship product, the disinfectant and deodorizing stick ' Dr. Clo', has recorded sales of over 14 million units worldwide. Hanryu and NON have committed to establishing business plans and product planning, developing products utilizing the FANTOO platform and characters, and exploring opportunities for product sales and supply. The FANTOO character, 'DeokGom', is slated to be integrated into the design of the disinfectant and deodorizing product 'Dr. Clo.' The product is scheduled for a future launch on TV home shopping.

09:10 EDT LPL Financial: Wealth Management joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Angelo Burns, Larisa Holiday, Eli Montoya and Manny Pedroza have joined LPL Financial's broker-dealer, RIA and custodial platforms. The team reported having served approximately $260 million in advisory, brokerage and retirement plan assets, and joins LPL from Corebridge Financial, formerly Valic, part of AIG.

09:07 EDT CareCloud in deals with MEDITECH for implementation partner at 3 institutions - CareCloud announced it recently solidified contracts to serve as the MEDITECH implementation partner for three esteemed healthcare institutions: La Paz Regional Hospital in Arizona, Russell Medical Center in Alabama, and Memorial Hospital and Manor in Georgia.

09:05 EDT Broadcom says court rules Netflix infringing on video patent - Broadcom (AVGO) announced that the District Court of Munich, Germany, ruled that Netflix (NFLX) is infringing a Broadcom patent related to HEVC/H.265 video coding. The court issued an injunction requiring Netflix to cease and desist all further infringement in Germany. Since 2018, Netflix and Broadcom have been engaged in a wide-ranging patent dispute whereby Broadcom has accused Netflix of infringing numerous U.S., German, and Dutch patents through its provision of its video streaming service. The European patent at issue in this ruling, EP 2 575 366, covers key features of digital video processing often used in HEVC/H.265 video coding. The court, on September 19, 2023, ruled that Netflix is infringing the '366 Patent through its transmission of HEVC video, which Netflix employs to provide Ultra HD content to its users. The resulting court-ordered injunction prohibits Netflix from providing certain video streaming services utilizing Broadcom's patented technology.

09:03 EDT Piper Sandler appoints Avey, Gerber as co-heads of public finance - Piper Sandler Companies has named Dustin Avey and Jeremy Gerber as co-heads of public finance. Avey and Gerber will report to Deb Schoneman, president at Piper Sandler. Frank Fairman, current head of public finance, will remain with the firm in an advisory capacity into 2024. Avey has been with the firm since 2007. Gerber has been with the firm since 2011.

09:03 EDT Eguana Technologies, Virtual Peaker partner with MMWEC for NextZero program - Eguana Technologies and Virtual Peaker have partnered with the Massachusetts Municipal Wholesale Electric Company to join their NextZero Connected Homes Program. This partnership is the newest addition to its rapidly growing roster of US utility operator partners, as virtual power plants continue to expand across the United States energy storage market. The Connected Homes program offers customers of participating Member utilities technology to better utilize smart appliances and devices, such as Eguana's home energy storage battery systems, to better manage their electric load. This generates cost savings and reduces the carbon footprint of both the utility and its customers. Homeowners will benefit from upfront rebates on Eguana systems and monthly rewards for participating in the program.

09:03 EDT Scynexis recalling Brexafemme from market, placing temporary hold on studies - In a regulatory filing, Scynexis (SCYX) stated: "Following a recent review by GSK of the manufacturing process and equipment at the vendor that manufactures the ibrexafungerp drug substance, Scynexis became aware that a non-antibacterial beta-lactam drug substance is manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA guidance recommends segregating the manufacture of beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been contaminated with a beta-lactam compound and Scynexis has not received reports of adverse events established to be due to the possible beta-lactam cross contamination. Nonetheless, in light of this risk and out of an abundance of caution (and aligned with GSK's recommendation), Scynexis is recalling Brexafemme ibrexafungerp tablets from the market and placing a temporary hold on clinical studies of ibrexafungerp, including the Phase 3 MARIO study, until a mitigation strategy and a resupply plan are determined."

09:00 EDT Nio 'currently has no reportable capital raising activity' - Nio said, "The Company has been made aware of certain media speculations claiming that the Company is considering raising certain capital from investors, which have been widely circulated today. In light of the unusual market activity in the Company's American depositary shares today, the Company would like to clarify that the Company currently has no reportable capital raising activity, other than the recent convertible notes offering that was completed on September 25, 2023. The Company is committed to maintaining transparent and timely communication with the public market, and will promptly announce any material information in accordance with applicable laws, listing rules, and best corporate practices."

09:00 EDT Scynexis trading resumes

08:58 EDT PharmAla Biotech receives first office action for PharmAla-1 PCT filing - PharmAla Biotech has received the first office action from the Patent Cooperation Treaty filing for the company's novel PharmAla-1 molecule. The filing for P-1 showed the molecule to be novel, with no previous Prior Art shown; It was also found to be inventive, due to the beneficial toxicology of P-1 compared to similar molecules, as shown by preclinical rodent model data generated by the laboratory of Prof. William Fantegrossi at the University of Arkansas for Medical Sciences. PharmAla-1 was first discovered through computational in-silico modelling exercises via PharmAla Biotech's partnership with the University of Windsor, for which PharmAla has also received a grant from the Ontario Centres for Innovation. Proof-of-concept testing for P-1 showed significant efficacy and pro-social effect at dosage levels far lower than MDMA, PharmAla's primary comparator molecule, as well as excellent safety pharmacology. P-1 is not considered a controlled substance anywhere in the world.

08:42 EDT Ainos enters securities purchase agreement with Lind Global Fund II - Ainos has entered into a securities purchase agreement with Lind Global Fund II LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager to issue and sell the initial $3 million tranche of a total anticipated $10 million private placement with $2 million funded at closing and $1 million to be funded subject to shareholder approval, effective registration statement and conditions specified in the agreement. The investment is in the form of a Senior Secured Convertible Promissory Note. The Note has an 18-month maturity. In addition, the Note will be convertible into Ainos' shares of common stock at an initial conversion price equal to $1.50 per share and subject to adjustment as further specified in the Note. The Note will be repayable in cash upon maturity. Prior to maturity, the Investor can convert to common stock at conditions specified in the agreement, following the earlier of 90 days from closing or effective registration statement. The Note contains certain prepayment options and participation rights. The private placement is subject to customary closing conditions. As part of the investment, the Investor was also granted five-year warrants equal to 75% of the funded amount at an initial exercise price equal to $0.90 per share of common stock, subject to adjustment. Maxim Group LLC is acting as the lead placement agent for the private placement. Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as the co-placement agent for the private placement. Ainos has agreed to file a registration statement registering for the resale of the shares of common stock issuable upon the conversion of the Note and upon the exercise of the warrants. Upon the shareholder approval and effectiveness of the resale registration statement, and subject to the satisfaction of certain conditions, additional tranches of funding may be provided by mutual agreement of the Investor and the Company in the aggregate amount up to $7.0 million. The Investor will be entitled to receive an additional warrant equal to 75% of the increased funding amount with an exercise price equal to 125% of the average of the ten daily VWAPs during the ten trading days prior to the subsequent closing date. Ainos plans to use the proceeds from this financing to fund clinical trials, commercial product launch, and working capital.

08:39 EDT Nature Wood Group in strategic pacts to launch supramolecular materials project - Nature Wood Group Limited announced its Chinese subsidiary Foshan City Linjia Technology Company Limited has entered into a framework agreement with the Research Institute of Wood Industry, Chinese Academy of Forestry on September 22 pursuant to which Linjia Tech has formed a five-year innovative partnership with the Research Institute on the research and development in relation to biomass supramolecular and biomass carbon electrode new materials. This collaboration marks a significant stride towards advancing biomass carbon innovation, with both parties dedicated to propelling advancements in biomass supramolecular and biomass carbon electrode materials. Under the Framework Agreement, the Research Institute will carry out research and development work according to the technological requirements put forward by Linjia Tech and promote the technological innovation of Linjia Tech on new biomass supramolecular materials. The Research Institute will offer to transfer to Linjia Tech in priority of any of its technological achievements relating to biomass carbon. The Research Institute will also provide technical service to Linjia Tech's information exchange home and abroad on new biomass supramolecular materials, deploy experts to Linjia Tech for technical support and organize teachers and students to Linjia Tech to carry out scientific research practice activities, etc. Both parties will jointly participate in various scientific and technological projects promoted by the national or local governmental bodies and carry out exchanges and discussions on relevant policies, industry trends and market developments, etc. Both parties are committed to strengthening the innovative research work in the field of biomass supramolecular and biomass carbon electrode new materials to drive the development of sustainable batteries from renewable sources worldwide.

08:36 EDT Coherus Biosciences receives FDA CRL for UDENYCA ONBODY BLA - Coherus BioSciences announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the Biologics License Application supplement for UDENYCA ONBODY, the company's on-body injector presentation of UDENYCA, solely due to an ongoing review of inspection findings at a third-party filler. The CRL did not identify any issues with the UDENYCA ONBODY clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing, and no additional data or trials have been requested. Coherus is committed to working closely with the FDA and the third-party filler to bring UDENYCA ONBODY to cancer patients requiring pegfilgrastim treatment as quickly as possible. Coherus also announced today that the FDA has completed the clinical study site inspections of three clinical sites in China that enrolled subjects in the two pivotal clinical trials supporting the toripalimab BLA for the treatment of metastatic or recurrent nasopharyngeal carcinoma as first-line treatment or as second or greater line treatment. Only one site received an FDA Form 483, with one observation noted. Coherus believes the observation is readily addressable. Coherus continues to anticipate potential approval for toripalimab by year end 2023.

08:32 EDT Grayscale Investments announces brand refresh - Grayscale Investments is celebrating the 10th anniversary of both the firm and its flagship fund, Grayscale Bitcoin Trust, by unveiling its 2023 brand refresh - reflecting the firm's decade-long evolution, as well as its future-forward commitment to investors. Grayscale's business was built embracing U.S. financial rules and regulations, underpinned by one fundamental belief: investors deserve transparent, regulated access to crypto. Since 2013, Grayscale has spearheaded digital asset investing and is proud to have grown GBTC into the world's largest Bitcoin investment vehicle. "Over the last decade, we have created a family of 18 proven investment products, which provide innovative exposure to the crypto ecosystem. To honor our heritage and convey our excitement for the next decade, today we are unveiling our new brand," said Grayscale CEO Michael Sonnenshein. "Our goal was to reimagine our brand with visual elements that reflect Grayscale's mission, vision, and values. At Grayscale, we believe everyone should have access to the digital economy, and we will always strive to be the asset manager of choice for savvy, future-focused investors around the world."

08:31 EDT ATIF Holdings unit signs agreement with Genehope - ATIF Holdings announces that its subsidiary, ATIF Business Management LLC, has entered into a services agreement with Genehope Holdings and, pursuant to the terms of the agreement, provides it with corporate advisory services. Through many in-depth communications and conversations, ATIF has fully understood Genehope's strategic planning and corporate needs, and conducted preliminary due diligence on Genehope to deeply understand its business model, market size and development prospects. The two sides reached a consensus on promoting Genehope's high-quality development through capital market, and formally signed a service agreement.

08:16 EDT Osisko, Bonterra enter agreement for exploration earn-in, JV on Urban-Barry - Osisko Mining (OBNNF) entered into a binding letter agreement with Bonterra Resources (BONXF) for a 70% exploration earn-in and joint venture on all of the Urban-Barry properties held by Bonterra, in addition to the adjoining Duke and Lac Barry properties, all located in Quebec's Eeyou Istchee James Bay region. The Duke property is currently 70% owned by Bonterra and 30% owned by Osisko, and the Lac Barry property is currently 85% owned by Bonterra and 15% owned by Gold Royalties Corp. The Properties total 496 claims over 22,508 hectares. Under the binding letter agreement, Osisko has agreed to pay Bonterra an initial upfront payment of $1 million in cash and an additional $4 million in cash upon the parties entering into the definitive agreement. Under the Exploration Earn-In, Osisko has agreed to fund $30 million in work expenditures over a three-year period to earn a 70% undivided interest in the Properties, in accordance with annual work expenditures $10 million in each year. After completion of the Exploration Earn-In, Osisko and Bonterra have agreed to form a joint venture entity or contractual joint venture in such form as the parties may agree, each acting reasonably, taking into consideration any tax and other factors relevant to the parties. During the Exploration Earn-In and upon and following the formation of the joint venture, Osisko will be the operator of the Properties. Upon completion of the Exploration Earn-In and the formation of the joint venture, Osisko and Bonterra will form a management committee to provide direction to the operator on exploration programs for the Urban-Barry Properties. Osisko and Bonterra have agreed to negotiate in good faith, settle, and enter into definitive documentation providing for the Exploration Earn-In as soon as practicable following the date hereof, subject to the satisfaction of certain customary conditions precedent. Osisko may withdraw from the Exploration Earn-In at any time upon written notice to Bonterra. In the event of an election to withdraw from the Exploration Earn-In, Osisko will forfeit all rights and interests in the Properties with no further liability, and the definitive documentation shall be immediately terminated upon such election.

08:14 EDT Affiliated Managers appoints Loren Starr to its Board of Directors - AMG, a leading partner to independent investment management firms globally announced the appointment of Loren M. Starr to its Board of Directors, effective immediately. Mr. Starr retired from Invesco in March 2021, having served as Chief Financial Officer of the company for 15 years, from 2005 to 2020, after which he held an executive advisory role as Invesco's Vice Chair until his retirement. Prior to joining Invesco in 2005, Mr. Starr served as the Chief Financial Officer of Janus Capital Group Inc. from 2001 to 2005, and held senior corporate finance roles with Putnam Investments, Lehman Brothers Inc., and Morgan Stanley & Co. LLC. Currently, he is an independent consultant, and is a member of the TIAA-CREF Fund Complex Boards of Trustees. Mr. Starr holds a B.A. and B.S. from Columbia University, an MBA from Columbia Business School, and an M.S. from Carnegie Mellon University.

08:12 EDT Gorilla announces strategic partnership with InfoSec Global, no terms - Gorilla Technology Group announced that it has started a strategic partnership with InfoSec Global, a leader and pioneer in crypto-agility. InfoSec Global helps clients establish the foundation of zero trust security through cryptographic agility management solutions. Gorilla has been at the forefront of developing cutting-edge solutions enabling governments to adapt efficiently to the evolving security landscape. The Smart Government Security Convergence solution facilitates better decision-making, proactive threat detection, and swift responses to emerging risks. With the partnership between Gorilla and InfoSec, the deployment of this groundbreaking solution is set to reach new heights.

08:12 EDT PDS Biotechnology reschedules KOL roundtable on HNSCC treatments - PDS Biotechnology Corporation announced that its Key Opinion Leader Roundtable on Addressing Current and Future Treatments for Recurrent/Metastatic Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma and the Potential Application of PDS0101 will now take place on Tuesday, October 3, 2023, from 8:00 - 9:00 AM EDT, due to a scheduling conflict. The event was originally scheduled for Wednesday, September 27, 2023.

08:10 EDT Asia Direct Cable Consortium selects Infinera's ICE6 800G solution - Infinera announced that Asia Direct Cable Consortium has selected Infinera's ICE6 800G coherent solution on the GX Series Compact Modular Platform to power ADC's advanced cable system. As the industry's highest-performing and most cost-effective solution for submarine networks, Infinera's ICE6 will enable ADC Consortium members to address surging demand for submarine cable capacity in Asia for bandwidth-intensive applications that include 5G networks, cloud-based services, and emerging solutions.

08:09 EDT Optiva launches MVNO Hubs on Google Cloud - Optiva announced the launch of Optiva MVNO Hubs on Google Cloud. The multi-tenant solution is offered as a SaaS product on Google Cloud in multiple regions worldwide, beginning with the Americas. Optiva MVNO Hubs include deep integration with Google Cloud's BigQuery for BSS-data-based, AI-powered insights. These regional MVNO hubs provide the complete Optiva BSS Platform and key MVNO integrations with services such as payment gateway, taxation, customer care, chat, customer relationship management ticketing and a dealer portal for rapid onboarding and management of dealer channels. Multiple innovative digital MVNOs are already capitalizing on the time to market and fully integrated functionality of Optiva MVNO Hubs on Google Cloud, including innovative digital MVNOs in the United States.

08:08 EDT Air Canada orders 18 Boeing 787-10s - Boeing and Air Canada announced the carrier is selecting the 787 Dreamliner to further modernize and grow its fleet with an order for 18 787-10 widebody jets, with the option to purchase 12 more. The flag carrier of the country, Air Canada will deploy the new fuel-efficient airplanes as part of its broader strategy to reduce carbon emissions while expanding its global route network.

08:07 EDT BigCommerce announces launch of B2B Edition Invoice Portal - BigCommerce announced the launch of its new B2B Edition Invoice Portal for large B2B suppliers, manufacturers, distributors and wholesalers to modernize the invoice payment process. The B2B Edition Invoice Portal provides an enterprise-grade, out-of-the-box invoice payment experience that allows B2B merchants to incorporate invoice payments into a centralized online purchasing workflow through the B2B Edition Buyer Portal. B2B merchants will now have the potential to improve transaction efficiency, reduce operational burdens, and deliver seamless user experiences that can drive brand loyalty and repeat business.

08:05 EDT Biora Therapeutics submits IND application to FDA for BT-600 program - Biora Therapeutics announced submission of an Investigational New Drug IND application with the U.S. Food and Drug Administration FDA . The IND application supports the next phase of development of BT-600, a drug/device combination designed to use Biora's NaviCap ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the treatment of moderate to severe ulcerative colitis. "Today's announcement is an important milestone for Biora Therapeutics. The IND application leverages clinical device function study data from four separate studies in both healthy volunteers and patients with active ulcerative colitis, with more than 40 study participants receiving over 80 NaviCap devices," said Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics. "We look forward to initiating our phase 1 study in the US this year and advancing this technology, which we believe could lead to better patient outcomes in ulcerative colitis," continued Dr. Kelman. The FDA will review the application and determine the acceptability of the data before Biora begins its first clinical trial for BT-600. It is possible that the FDA will require additional information.

08:04 EDT Appili Therapeutics announces U.S. FDA approval of LIKMEZ - Appili Therapeutics announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, received approval from the U.S. Food and Drug Administration for Metronidazole Oral Suspension 500mg/5mL, ATI-1501. ATI-1501, Appili's liquid oral reformulation of the antibiotic metronidazole, has been licensed to Saptalis for commercialization in the U.S., and other selected territories. The FDA also approved LIKMEZ as the brand name for ATI-1501. "The FDA approval of LIKMEZ, shortly after securing patent coverage through 2039, is an important milestone that demonstrates Appili's ability to identify promising opportunities and develop and monetize them for the benefit of both patients and shareholders," said Don Cilla, Pharm.D., M.B.A., Appili's President and CEO. "Difficulty swallowing tablets and capsules should not be a barrier to accessing appropriate antibiotic therapy. LIKMEZ provides a convenient alternative for patients who have difficulty taking solid oral medicines." Dr. Cilla adds "Appili was formed to develop ATI-1501 and it is exciting to see our first development project make it to market. This is a tremendous team accomplishment. We are all delighted that the product will soon be available to patients and we look forward to bringing additional products to market that tackle serious global challenges in infectious disease."

08:03 EDT Jasper Therapeutics appoints Herb Cross CFO - Jasper Therapeutics announced the appointment of Herb Cross as the company's Chief Financial Officer CFO . Jeet Mahal, who previously held both CFO and Chief Operating Officer roles, will continue as the company's COO. Mr. Cross brings more than two decades of experience in financial leadership roles at both public and private biotechnology companies. Before joining Jasper, he served as CFO at Atreca, leading its initial public offering and holding responsibility for all administrative functions, including finance, corporate communications, human resources and corporate services. Prior to Atreca, he was CFO at ARMO BioSciences, with responsibility for all administrative functions and business development, and led its initial public offering and served as CFO through the sale of the company to Eli Lilly in 2018. Mr. Cross also served as CFO and interim Chief Executive Officer at KaloBios Pharmaceuticals and was CFO at Affymax as well. Mr. Cross began his career at Arthur Andersen and received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California.

08:02 EDT CoreCivic enters management contract with Hinds County - CoreCivic signed a new management contract with Hinds County, Mississippi for up to 250 adult male pre-trial detainees at the Company's 2,672-bed Tallahatchie County Correctional Facility in Tutwiler, Mississippi. The initial contract term is for two years, which may be extended for an additional year upon mutual agreement.

08:01 EDT Banxa provides business update for shareholders - Banxa Holdings provides shareholders an update on the Company's progress over the recent weeks. Holger Arians, CEO of Banxa Holdings Inc., stated, "Banxa is seeing continued success from many key business wins, highlighted by new blue-chip partners attracted to Banxa's leading payments infrastructure. Looking ahead, we see long-term upward trajectory thanks to our local regulatory and compliance strategy that we have aggressively pursued over the last number of years in anticipation of this next stage of compliant Web3 growth." Banxa continues to maintain a solid financial trajectory in the current bear market conditions and has set achieving cash flow breakeven as its primary objective. Some unaudited, preliminary financial highlights include: Unaudited Total Transaction Volume of approximately AUD $73.2M and AUD $74.8M in July and August 2023, respectively. Net take rate has improved to now be consistently sitting above 3%, due to increased operational efficiencies, compared to 1.8% in FY22. Total liquidity and cash position at the end of August 2023 stood at AUD ~$10.1M and AUD ~$5.1M, respectively. Furthermore, the Company is pleased to update shareholders on its considerable progress in growing its run rate total transaction volume by activating new major partnerships with noteworthy partners, and other business updates: Ledger, a major, global non-custodial wallet with millions of users has integrated Banxa to offer their users on-ramping services as of September 12th. Web3 gaming conglomerate Animoca Brands has integrated Banxa's NFT Checkout and crypto payments infrastructure to their Australian Football League Mint. The partnership went live on Friday 22nd of September. In August, one of the world's largest payments and transactional service providers, Worldline, integrated Banxa successfully to its Payment Orchestration, allowing all Worldline merchants to be able to activate Banxa's global crypto payment infrastructure instantly. Banxa is now working with Worldline to activate their merchants and initiate new partnerships together. Find out more here. Banxa now holds 32 Money Transmitter Licences in the USA, and is expecting 7 more MTLs to be granted in 2023. Banxa does not require MTLs to operate in 10 states / territories. Accordingly, Banxa is already capable of servicing 42 states / territories in the USA. Banxa also continues to deepen its relationships with key partners such as MetaMask, one of the largest digital wallets with more than 20 million users, to launch new features aimed to increase user experiences, conversion rates, and ultimately transaction volumes for both parties. The Company is announcing that members of the Management team including Domenic Carosa Chairman, Holger Arians CEO, Zafer Qureshi Director and Head of Corporate Affairs, Patrick Maguire CFO, Richard Mico U.S. CEO and Global Head of Legal, Risk & Compliance, Gregor Cooney CMO, Damien Di Cosmo Head of People & Culture and Phil Brown US CCO will participate in a round of open market share purchases over the coming days. These purchases are being made in adherence with Banxa's company share trading policies, and they have been pre-approved by the Chairman of the Board of Directors. Participating team members will file reports with Sedi in a timely manner.

07:46 EDT Genmab receives European Commission approval of TEPKINLY - Genmab announced that the European Commission has granted conditional marketing authorization for TEPKINLY as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union, as well as Liechtenstein, Norway and Iceland.

07:39 EDT Phillips Edison appoints Anthony Terry to serve as an independent director - Phillips Edison & Company announced that its Board of Directors has appointed Anthony "Tony" Terry to serve as an independent director, effective October 30. Jeff Edison, Chairman and Chief Executive Officer of PECO stated: "We are delighted to welcome Tony to PECO's Board. With more than three decades of public company business experience working with senior management and boards to drive growth and innovation, Tony brings a proven track record of substantial accomplishment in strategic planning, corporate and operational finance, regulatory matters and capital allocation."

07:37 EDT Soligenix achieves milestone with bivalent and trivalent filovirus vaccines - Soligenix announced two-year stability of its thermostabilized bivalent and trivalent filovirus vaccine candidates at temperatures of 40 degrees Celsius (104 degrees Fahrenheit) when formulated in a single vial, needing reconstitution only with sterile water immediately prior to use. This follows the previous successful demonstration of 100% protection of non-human primates against lethal Sudan ebolavirus and Marburg marburgvirus challenge with the bivalent vaccine. This important milestone is part of an ongoing collaboration with the University of Hawaii at Mnoa, demonstrating the successful presentation of one or more antigen(s) within the same formulation while maintaining full potency and thermostability, including vaccines for Sudan ebolavirus and Marburg marburgvirus. It further demonstrates the broad applicability of the heat stable vaccine platform, and its potential role in the United States Administration's initiative for pandemic preparedness.

07:35 EDT Accurate Meditech chooses Enovix standard IoT and Wearable-sized batteries - Enovix announced its standard IoT and Wearable-sized batteries have been chosen by Accurate Meditech for their Class II FDA-Approved "Mini" multi-vital sign monitor. The Accurate Mini continuously monitors blood pressure, pulse rate and other vital signs. Accurate Meditech received FDA clearance in June 2023. With an Enovix battery, the Mini is anticipated to last over four months on a single charge, a 35% improvement compared to standard graphite batteries. It will be available over the counter and sold at CVS, Walgreens and Walmart in the U.S. in the second half of 2024. "We chose Enovix due to its long-lasting battery because it's critical that our device runs as many hours as possible so that people can continuously monitor the status of their heart and other vital signs," said Stanley Wang, General Manager of Accurate Meditech. "Non-invasive health monitoring is efficient and effective and with more than 80 million people in the United States suffering from cardiovascular disease, working with Enovix, we're pleased to play a role in helping minimize risks with always-on, worry-free health monitoring."

07:34 EDT Theratechnologies, Marathon enters agreement in principle to amend loan facility - Theratechnologies has reached an agreement in principle to amend some of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time, with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager. The Company and Marathon agreed in principle to make the following amendments to the terms and conditions of the Loan Facility: to remove the obligation to maintain at all times liquidity in the amount of $30 million if the F8 formulation of tesamorelin is not approved by the United States Food and Drug Administration by March 31, 2024; to decrease the minimum liquidity requirements over time to a minimum of $15 million from $20 million based on targeted last twelve months adjusted EBITDA; to move to an adjusted EBITDA-based target from a quarterly revenue-based target beginning with the quarter ending November 30, 2023; and to delete from the Loan Facility the prohibition for the Company to have a going concern explanatory paragraph in the annual report of the independent registered public accounting firm of the Company. In consideration of the proposed amendments, the Company has agreed to pay an amount equal to $600,000, or 100 basis points calculated on the funded debt as of this day, over the term of the loan and added to the outstanding loan as payment in kind; and reprice the exercise price of the common share purchase warrants held by Marathon to $2.30 per share from $5.80 per share. Following the share consolidation completed on July 31, 2023, the exercise of four Warrants is required to purchase 1 common share of Theratechnologies, resulting in a maximum issuance of 1,250,000 common shares. The Warrants can be exercised until February 27, 2030. The repricing of the Warrants is conditional upon the approval of the Toronto Stock Exchange and the final terms of these amendments, including the definition of "adjusted EBITDA", remain subject to the completion of all the legal documentation to the satisfaction of both the Company and Marathon. The amendments to the Loan Facility are expected to be executed on or about October 10, 2023.

07:32 EDT FMC Corporation names Jacqueline Scanlan as new chief human resources officer - FMC Corporation announced that Jacqueline Scanlan has been named executive vice president and chief human resources officer. Scanlan will lead the global Human Resources function and assume responsibility for FMC's global Diversity, Equity and Inclusion strategy and team. She will report to Mark Douglas, FMC president and CEO. Scanlan is a seasoned HR professional with over 25 years of experience at multinational companies across various industries. She joins FMC from Axalta Coating Systems, where she served as senior vice president and CHRO since 2021. She has held senior HR roles at several leading companies, including Haemonetics Corporation, Novo Nordisk and Campbell Soup Company.

07:31 EDT MarineMax's Fraser Yachts to acquire controlling interest in Atalanta Golden - MarineMax announced that Fraser Yachts, its wholly owned subsidiary, has executed a definitive agreement to acquire a controlling interest of Atalanta Golden Yachts, a charter management agency based in Athens, Greece. John Dragnis, principal shareholder of Atalanta Golden Yachts, maintains a significant stake and will remain involved in the growth and development of Fraser's operations in Greece. The acquisition is expected to close in the quarter ending December 31, 2023, and be accretive in its first full year of operations. Brett McGill, MarineMax CEO and President, stated, "The addition of Atalanta Golden Yachts complements our leading superyacht brokerage and luxury yacht offerings and is a testament to our continued expansion into higher-margin businesses with global reach. Atalanta Golden Yachts' long-standing relationships and network of clients, combined with Fraser Yachts' full-service yachting offerings, strengthens our commitment to providing unparalleled luxury yachting experiences to a growing number of customers worldwide. We are thrilled that the Atalanta Golden Yachts team will be joining our Fraser team in Greece and look forward to further solidifying our position in this attractive and growing market."

07:13 EDT e.GO's registration statement for combination with Athena declared effective - Next.e.GO Mobile and Athena Consumer Acquisition announced that the U.S. Securities and Exchange Commission, SEC, has declared effective the registration statement on Form F-4 of e.GO in connection with its proposed business combination among e.GO, Athena, Next.e.GO B.V., a wholly-owned subsidiary of e.GO, and Time is Now Merger Sub, Inc., a wholly-owned subsidiary of TopCo. Athena has scheduled the special meeting of its stockholders and the special meeting of its warrant holders for September 28, 2023 to, among other things, approve the proposed Business Combination and the proposed warrant exchange which will become effective immediately prior to the closing of the Business Combination. Isabelle Freidheim, Chairman of Athena, said: "The declaration of the SEC effectiveness is a significant step towards the successful completion of the business combination between Athena and e.GO. We have diligently sought out a partner that aligns with our vision, and we are confident that this transaction will position us for long-term success. We at Athena are incredibly excited to be partnering with e.GO on this transaction because we believe e.GO is a truly disruptive company, one that can contribute meaningfully to solving the challenges of electric mobility in the urban environment."

07:12 EDT Asante Gold announces additional drill results at Aboduabo Project - Asante Gold announces results from its ongoing exploration drilling program at the Aboduabo prospect located on our Bibiani - Chirano mines corridor, Sefwi Greenstone Belt, Ghana. Latest drill results have intersected high grade shoot extensions in multiple zones down-plunge of the defined +1km strike length of Aboduabo mineralization. Previous announcements by the Company have highlighted the significant intercepts and potential of this deposit, located along the Bibiani Shear Zone. To date, 88 holes totaling 21,000m have been completed testing lateral extensions and upgrading geologic confidence in previously tested zones. Field mapping has been initiated along the trend to identify new targets for future growth. Highlights: CHRC3406 intersected a high gold grade shoot extension of significant interest, grading 8.73 g/t over 20.5m; Step-out drilling has intersected consistently wide, significant gold mineralization within metasedimentary shear zones. Selected intercepts include: CHRC3406D - 20.5m @ 8.73 g/t Au from 222 to 242.5m; CHRC3420D - 10.1m @ 5.83 g/t Au from 214.7 to 224.8m; CHRC3405D - 17.15m @ 4.27 g/t Au from 274.5 to 291.65m Includes 7.7m @ 8.94 g/t Au from 274.5m to 282.2m; CHRC3386D - 30m @ 2.81 g/t Au from 120m to 150m Includes 24m @ 3.16 g/t Au from 126m to 150.0m; CHRC3400D - 26.6m @ 2.27 g/t Au from 166.35m to 192.95m Includes 8.3m @ 4.2 g/t Au from 169.7m to 178.0m; CHRC3411D - 65.0m @ 1.41 g/t Au from 46.0m to 111.0m Includes 24.20m @ 2.47 g/t Au from 46.0m to 70.2m; CHRC3441D- 46.70m @ 1.90 g/t Au from 380.3.0m to 427.0m Includes 10.0m @ 4.37 g/t Au from 402.1m to 413.0m. Dave Anthony, President and CEO stated, "Results from the exploration drill program at Aboduabo continue to support our assessment that the deposit remains open and has potential to develop into long life open pit mine and future underground mine. We look forward to expanding the Aboduabo footprint with our field mapping program."

07:10 EDT NaaS establishes strategic partnership with CIID - On September 22, NaaS established a strategic partnership with Hubei Provincial Communications Investment Industrial Development Co., Ltd. NaaS will fully leverage its capability in one-stop construction and operation of public charging infrastructure, integrated PV-storage-charging service and digital and intelligent application of new energy. By combining its services with CIID's expressway network and energy supply stations, NaaS contributes to the construction of expressway service areas and energy supply infrastructure, thus accelerating the establishment of a comprehensive energy supply network for expressways. At the signing ceremony, CIID officially released the new brand named "Chu Dao Yi Neng" , which will carry the new energy business sector of CIID, working collaboratively with partners to empower the construction of Hubei expressways charging infrastructure system. According to the contract, NaaS will provide services for gas stations and charging stations under CIID's 48 expressway service areas. This include connected refueling and charging services as well as mobile charging device deployment and operation services during public holidays.

07:08 EDT Sprott Private Resource Lending Fund III completes final closing - Sprott announced that Sprott Private Resource Lending Fund III has completed its final closing. With the close of Fund III, total assets under management of Sprott Resource Lending Corp stands at $1.5B within the Company's private strategies segment.

07:06 EDT Eledon:Tegoprubart used as part of imunosuppressive regimen post transplant - Eledon Pharmaceuticals announced that tegoprubart, the company's investigational anti-CD40 antibody, was used as a cornerstone component of the chronic immunosuppressive regimen administered following the second-ever transplant of a genetically modified heart from a pig to a human. The procedure was completed on September 20th at University of Maryland Medical Center on a 58-year-old male suffering from heart failure. "This is a momentous milestone for the transplant community and serves as a testament to the continued progress being made towards advancing novel treatment options for patients requiring an organ transplant," said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. "As the field of organ transplantation continues to make important scientific advances, Eledon is dedicated to delivering a novel immunosuppressive regimen with the potential to protect and prevent rejection of transplanted organs, and we are honored to play a role in this historic development." Following the successful transplantation, tegoprubart was administered to the patient as a novel, key component of a chronic immunosuppressive regimen designed to suppress the immune system and prevent the body from rejecting the implanted organ. In prior clinical research, tegoprubart has demonstrated a favorable safety and tolerability profile across multiple indications, including kidney transplantation, as well as clinical benefit in the prevention of rejection and the protection of organs after transplantation.

07:03 EDT Alcoa names William Oplinger as CEO, Roy Harvey becomes strategic advisor to CEO

07:02 EDT Alcoa appoints William Oplinger as president and CEO, succeeding Roy Harvey - Alcoa Corporation announced that William F. Oplinger has been elected to serve as President and CEO of the company and as a member of its Board of Directors. Oplinger succeeds Roy C. Harvey, effective September 24, 2023, who will serve as Strategic Advisor to the CEO until December 31, 2023. Oplinger has served as the company's Executive Vice President and COO since February 2023 and previously served as the company's Executive Vice President and CFO from November 2016 to February 2023. The transition of the President and CEO roles reflects the company's succession planning process.

07:01 EDT Cytomed Therapeutics says iPSC-based technology granted patent by CNIPA - CytoMed Therapeutics announced that its exclusively licensed induced pluripotent stem cell-based technology has been granted a patent by the China National Intellectual Property Administration. The patent titled "Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells" with Patent No. ZL201880022790.X, published as CN 110691844 B, covers technologies to derive novel synthetic gammadelta NKT cells for the treatment of various types of cancers including hematological malignancies and solid tumors. This asset is currently under preclinical development. The Company holds an exclusive, worldwide license to use this patent pursuant to the Licence Agreement dated June 1, 2018, which was filed with the SEC as an exhibit to the registration statement on Form F-1 (File No.: 333-268456) on March 30, 2023.

06:56 EDT Aliant Communications acquires Sierramotion, terms not disclosed - Allient announced that it has acquired Sierramotion, a privately-owned company specializing in designing and engineering turn-key motion components and mechatronic solutions for robotic, medical, industrial, defense, semiconductor and other precision applications. Financial terms of the transaction were not disclosed.

06:49 EDT GFL Environmental reprices senior secured term loan - GFL Environmental has amended its $729M senior secured term loan to reduce its borrowing rate to SOFR + 250 basis points from the previous SOFR + 300 basis points, plus 10 basis points CSA, resulting in a total borrowing rate reduction of 60 basis points.

06:33 EDT Ault Inc. announces strategic corporate alignment - Ault Alliance announced its plans to execute a strategic corporate alignment of the company and its subsidiaries. To adapt to current market dynamics, Ault Alliance has unveiled its strategic plan to restructure its corporate blueprint. This transformation is meant to emphasize the unique strengths and individual growth paths of each subsidiary's operations. The new structure focuses on three central subsidiaries being Circle 8 Crane Services LLC, Sentinum Inc., and Ault Venture Group. This realignment permits specialized management and resource allocation to each individual subsidiary while preserving the adaptability for possible separations into standalone entities in response to future market dynamics. Circle 8 will continue to focus its attention on supplying premier crane and heavy machinery rental services. Circle 8 is focused on the energy sector and serve a diverse client base in the South Central U.S. Sentinum is positioned to address the surging demand for data center infrastructure to provide colocation and hosting services for the emerging artificial intelligence ecosystems and other industries. With its existing facilities along with its planned buildout of its Montana and Texas sites, Sentinum is well-positioned to deliver top of the line data center solutions. The Company's Bitcoin mining operations are hosted by Sentinum with 14,599 S19j Pro Antminers and 4,628 S19 XP Antminers in operation. Ault Venture Group will house all other subsidiaries and ventures and serve as the investment cornerstone of Ault Alliance. Notably, Ault Venture Group will house Ault Lending, Ault Global Real Estate Equities, and Ault Alliance's ownership of other public companies such as The Singing Machine Company, Inc, and BitNile Metaverse, Inc. After this strategic restructuring, the Company will embark on an extensive assessment of its existing assets and investments to determine potential strategic dispositions. The company has already begun certain strategic dispositions including the distribution of securities of Imperalis Holding Corp, d/b/a TurnOnGreen, Inc., the listing for sale of its Midwest hotel portfolio and the upcoming listing of its St. Petersburg, FL multifamily development project.

06:31 EDT Honeywell, ESS Inc. announce strategic collaboration - Honeywell (HON) announced a strategic collaboration with ESS Tech (GWH) to advance technology development and market adoption of iron flow battery energy storage systems. Honeywell has made an investment in ESS as part of this collaboration. The relationship builds upon each company's development of energy storage systems, and brings together ESS' market-leading, patented IFB design with Honeywell's advanced materials and energy systems expertise.

06:21 EDT Novartis reports Phase 3 NETTER-2 trial met primary endpoint - Novartis announced the Phase III NETTER-2 trial with Lutathera met its primary endpoint. First line treatment with Lutathera in combination with long-acting octreotide demonstrated a significant improvement in progression-free survival, or PFS, in patients with newly diagnosed somatostatin receptor-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, versus high-dose long-acting octreotide alone. No new or unexpected safety findings were observed in the study and data are consistent with the already well-established safety profile of Lutathera, the company stated. "These positive results for Lutathera are quite remarkable and they represent the potential for radioligand therapy to make a meaningful impact for newly diagnosed patients living with advanced GEP-NETs," said Jeff Legos, Executive Vice President, Global Head of Oncology Development at Novartis. "Exploring the use of radioligand therapies in earlier lines of treatment for patients with cancer is part of our larger, collaborative effort to precisely deliver novel treatment modalities directly to the cancer cells to improve patient outcomes." The findings from NETTER-2 will be presented at an upcoming medical meeting and discussed with regulatory authorities.

06:15 EDT Target unveils plans for Target Circle Week event - Target Corporation unveiled plans for its Target Circle Week event Oct. 1-7, exclusively for members of Target Circle, its free-to-join loyalty program. With deep discounts on hot, trending gifts, seasonal items, everyday essentials and more, Target is offering a full week of savings on thousands of products across its assortment. In addition to deep savings on top products and brands, members will also receive exclusive access to special offers from Shipt, Ulta Beauty at Target and Tripadvisor. Target's more than 100 million Circle members can shop Target Circle Week deals in stores, online and on the Target app. Anyone who isn't yet a member can quickly and easily join for free at Target.com/circle to access the Target Circle Week deals, plus additional perks, personalized offers and more all year long.

06:14 EDT KBR awarded EPCm contract by Woodside Energy for Pluto LNG - KBR (KBR) has been awarded an engineering, procurement and construction management contract by Woodside Energy (WDS), as operator for and on behalf of the Pluto Joint Venture. Under the contract, KBR will undertake modifications to Train 1 of Woodside's Pluto LNG facility, located near Karratha, Western Australia. The modifications will enable the processing of up to three million tonnes per annum of Scarborough gas through Train 1.

06:10 EDT Booking Holdings to appeal EC decision to prohibit acquisition of Etraveli Group - Booking Holdings announced that it intends to appeal the European Commission's recently announced decision to prohibit the company's acquisition of Etraveli Group, from CVC Capital Partners, to the European courts.The company strongly believes the Commission is wrong on both the facts of the case and the law applicable to this transaction, which was cleared unconditionally by multiple competition authorities, including the UK Competition & Markets Authority and U.S. FTC. The Commission has fundamentally misconstrued the highly competitive travel markets for flights and accommodations, and its decision is an unexplainable departure from the Commission's own Non-Horizontal Merger Guidelines, which are legally binding on the Commission. The acquisition, which would have combined two separate but complementary Europe-based businesses operating within separate, highly competitive industries, would have delivered tremendous benefits for consumers and partners by bringing more options and competitive pricing. Booking Holdings regrets very much the lack of convergence of the European Commission with other major international enforcers on this pro-competitive transaction. The European Commission's decision does not alter Booking Holdings' commitment to continue building its already growing and successful flights offering at Booking.com, and providing increased choice and transparency for consumers, as the company today also announces an extension of an existing and long-standing commercial partnership agreement between Booking.com and Etraveli Group through at least December 2028. While the acquisition would have allowed Booking.com to fully harness all of Etraveli Group's capabilities and management team to offer a better flights product and better deals for consumers through, among other things, greater strategic and commercial alignment and enhanced integration, the continued partnership with Etraveli Group will further strengthen and accelerate Booking.com's ongoing work to build a frictionless global flights offering, which is already live in over 50 countries, and deliver even more value to travelers.

06:09 EDT Imax responds to Letko's statement on proposed privatization of IMAX China - "With reference to the announcement made by Letko, Brosseau & Associates Inc. on September 22, 2023 stating its intention to vote against the take private transaction, IMAX Corporation reiterates its belief that the transaction is in the best interests of IMAX China shareholders and represents a compelling offer. While IMAX China's first half results are encouraging reflecting both theatre re-openings and increased box office market share, IMAX China's share price continued to exhibit weakness and its trading volume hit all-time lows throughout 2023 prior to the proposed privatization transaction despite market awareness of IMAX China's results through weekly box office reporting and the first quarter results released by IMAX Corporation on April 27, 2023. IMAX China's volume weighted average price for the 30 and 90 full trading days prior to the transaction announcement was $6.46 and $7.50. We believe that major contributory factors to the historical share price weakness are a lack of trading liquidity, low institutional ownership and declining research coverage - all of which will remain unchanged should the transaction fail to receive shareholder approval. The proposal provides IMAX China shareholders with HK$10.00 per share in cash, which could be reinvested in IMAX Corporation's shares for those shareholders interested in participating in the company's continued growth in China."

06:07 EDT Ardelyx: Kyowa Kirin's NDA for tenapanor approved in Japan - Ardelyx announced that its collaboration partner in Japan, Kyowa Kirin Co., has received approval from the Japanese Ministry of Health, Labour and Welfare for the New Drug Application for tenapanor for the improvement of hyperphosphatemia in adult patients with chronic kidney disease on dialysis. Tenapanor will be marketed with the brand name PHOZEVEL in Japan. This approval triggers an aggregate of $30 million from Kyowa Kirin to Ardelyx in milestone payments and payments under the recent amendment to the license agreement between Ardelyx and Kyowa Kirin. As a result of this approval, Ardelyx will also receive a $5 million payment under the terms of its agreement with HealthCare Royalty Partners. In addition, Ardelyx may also receive an additional $5 million from Healthcare Royalty Partners in the event net sales in Japan exceed a certain target by 2025.

06:05 EDT Reviva Pharmaceuticals: Last patient evaluated in Phase 3 RECOVER trial - Reviva Pharmaceuticals announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia has now completed the study. Topline data from RECOVER are expected in October 2023. Brilaroxazine is a serotonin-dopamine stabilizer with multifaceted activity designed to improve schizophrenia symptoms and accompanying neuroinflammation.

06:03 EDT Regal Rexnord to sell Industrial Motors and Generators business to WEG - Regal Rexnord (RRX) has entered into a definitive agreement to sell the Industrial Motors and Generators businesses that comprise the majority of its Industrial Systems segment to WEG, through certain subsidiaries of WEG S.A. (WEGZY), for total consideration of $400M. The closing of the transaction, which is subject to obtaining required regulatory approvals and meeting customary closing conditions, is expected to occur in the first half of 2024. Regal Rexnord CEO, Louis Pinkham, commented on the agreement: "After a thorough strategic review, we believe this transaction with WEG will be a true win-win for both companies' principal stakeholders. The sale of our Industrial Motors and Generators businesses is consistent with our strategy of focusing the portfolio on products, sub-systems, end markets and/or applications where we can achieve GDP-plus growth rates and gross margins above 35%. While we have made significant progress improving the growth prospects and margins at these businesses, we believe that WEG is in a better position to accelerate their performance going forward. Consistent with our previously stated capital deployment intentions, all available net proceeds from the transaction will be used to reduce our debt. In combination with Regal Rexnord's strong expected organic cash flow generation, we remain on track to reduce our net leverage ratio to below 2.5x by 2025."

05:58 EDT Alvotech says Fuji Pharma Co receives marketing approval for AVT04 - Alvotech announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd., has received marketing approval for AVT04, a biosimilar to Stelara, from the Japanese Ministry of Health, Labor and Welfare. Based on publicly available information, AVT04 is the first biosimilar to Stelara to be approved for sale in global markets. Global sales of Stelara reached over $10B for the twelve months preceding June 30, 2023, according to the manufacturer's public filings, making it one of the world's highest grossing biologics.

05:55 EDT Biogen, Eisai announce LEQEMBI Intravenous Infusion approved in Japan - Eisai (ESAIY) and Biogen (BIIB) announced that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI Intravenous Infusion has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease. Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.